000048556 000__ 01446nam\a2200433\i\4500
000048556 001__ 48556
000048556 003__ SzGeWIPO
000048556 005__ 20231204174304.0
000048556 006__ m    eo  d        
000048556 007__ cr bn |||m|||a
000048556 008__ 231029s2023\\\\nju\\\\\o\\\\\000\0\eng\d
000048556 0247_ $$a10.1111/jwip.12269$$2doi
000048556 035__ $$a(OCoLC)1411270402
000048556 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000048556 041__ $$aeng
000048556 24500 $$aWhy patent waiver for Covid-19 vaccines and pharmaceuticals?
000048556 264_1 $$a[Hoboken, New Jersey] :$$bJohn Wiley & Sons Ltd,$$c2023
000048556 300__ $$a1 online resource (pages 195-226)
000048556 336__ $$atext$$2rdacontent
000048556 337__ $$acomputer$$2rdamedia
000048556 338__ $$aonline resource$$bcr$$2rdacarrier
000048556 4901_ $$aJournal Of World Intellectual Property,$$x1747-1796 ;$$v26, 2, 2023
000048556 588__ $$aCrossref
000048556 590__ $$aPublished online: 6-Apr-23
000048556 650_4 $$aIntellectual property$$xLaw and legislation
000048556 650_0 $$aVaccines.
000048556 650_0 $$aPatents$$xLaw and legislation.
000048556 650_0 $$aPharmaceuticals.
000048556 650_0 $$aCOVID-19 pandemic.
000048556 650_0 $$aPatents.
000048556 650_0 $$aIntellectual property.
000048556 650_0 $$aCopyright.
000048556 7001_ $$aKumar, Mrityunjay,$$eauthor.
000048556 7001_ $$aBharti, Nalin,$$eauthor.
000048556 7731_ $$tJournal of World Intellectual Property$$wJWIP
000048556 830_0 $$aJournal Of World Intellectual Property,$$x1747-1796 ;$$v26, 2, 2023.
000048556 85641 $$uhttps://doi.org/10.1111/jwip.12269$$yOnline version
000048556 904__ $$aArticle
000048556 980__ $$aJWIP